Actuate Therapeutics (ACTU) EBITDA Yield: History & Chart

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T21:50:34.173Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:50:34.173Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -20,772,595
Quote market capitalization: 19,418,221
Total debt · period ending 2026-06-30: 404,991
Cash · period ending 2026-06-30: 4,425,841

FMP input reference: a29a88061d86e64317c53e71c63756e58f7ffa0b55551e6148327154cc786467

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

ACTU EBITDA Yield Metrics

EBITDA YIELD

N/A

ACTU Competitors' EBITDA Yield

ACTU

Actuate Therapeutics Inc

Current

Market Cap

$19.42M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

QNTM

Quantum BioPharma Ltd.

vs ACTU

Market Cap

$19.77M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NEUP

Neuphoria Therapeutics Inc.

vs ACTU

Market Cap

$18.65M

EBITDA Yield

N/A

TTM Avg

4.87%

3Y Avg

4.87%

5Y Avg

4.87%

PIII

P3 Health Partners Inc.

vs ACTU

Market Cap

$18.41M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ESLA

Estrella Immunopharma, Inc.

vs ACTU

Market Cap

$18.30M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NXTC

NextCure, Inc.

vs ACTU

Market Cap

$20.53M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COSM

Cosmos Health Inc.

vs ACTU

Market Cap

$17.39M

EBITDA Yield

N/A

TTM Avg

2.57%

3Y Avg

2.17%

5Y Avg

2.17%

LPCN

Lipocine Inc.

vs ACTU

Market Cap

$17.31M

EBITDA Yield

N/A

TTM Avg

6.12%

3Y Avg

6.12%

5Y Avg

6.12%

PAVM

PAVmed Inc.

vs ACTU

Market Cap

$17.07M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MRKR

Marker Therapeutics, Inc.

vs ACTU

Market Cap

$16.84M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Actuate Therapeutics Inc (ACTU)	$19.42M	N/A	N/A	N/A	N/A
Quantum BioPharma Ltd. (QNTM)vs ›	$19.77M	N/A	N/A	N/A	N/A
Neuphoria Therapeutics Inc. (NEUP)vs ›	$18.65M	N/A	4.87%	4.87%	4.87%
P3 Health Partners Inc. (PIII)vs ›	$18.41M	N/A	N/A	N/A	N/A
Estrella Immunopharma, Inc. (ESLA)vs ›	$18.30M	N/A	N/A	N/A	N/A
NextCure, Inc. (NXTC)vs ›	$20.53M	N/A	N/A	N/A	N/A
Cosmos Health Inc. (COSM)vs ›	$17.39M	N/A	2.57%	2.17%	2.17%
Lipocine Inc. (LPCN)vs ›	$17.31M	N/A	6.12%	6.12%	6.12%
PAVmed Inc. (PAVM)vs ›	$17.07M	N/A	N/A	N/A	N/A
Marker Therapeutics, Inc. (MRKR)vs ›	$16.84M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

ACTU EBITDA Yield Metrics

ACTU Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics